Editas Medicine Inc

NASDAQ:EDITUnited States

Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

Contact Information

Headquarters

11 Hurley StCAMBRIDGE, MA, United States 02141-2110

Phone

617-401-9000

Fax

302-655-5049

Executives

Executive Chairman of the Board

James Mullen

President, Chief Executive Officer, Director

Gilmore O Neill

Chief Financial Officer, Executive Vice President

Michelle Robertson

Executive Vice President, Chief Scientific Officer

Mark Shearman

Executive Vice President, Chief Business Officer

Bruce Eaton